Document Detail


Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
MedLine Citation:
PMID:  15345759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: It is now generally accepted that the use of second-generation, or atypical, antipsychotics for schizophrenia represents an advance over conventional antipsychotic agents. However, adherence continues to be a problem, as with other medications for chronic disorders. Long-acting formulations of conventional antipsychotics partly address adherence problems, but their use is limited by tolerability issues. This article provides practical advice to physicians on the characteristics of patients who would benefit from treatment with long-acting atypical antipsychotic agents and offers suggestions on how to initiate treatment. METHODS: A literature search for studies published between 1980 and 2003 that evaluated the treatment of patients with schizophrenia with long-acting atypical agents was conducted by using MEDLINE and EMBASE. The primary search parameters were "schizophrenia," "atypical," "antipsychotic," and "long-acting." As expected, long-acting risperidone was the only long-acting atypical agent identified; thus this article focuses on practical advice and suggestions on how to initiate therapy with long-acting risperidone. RESULTS AND DISCUSSION: From the results of the literature search and the discussion of a panel of experts at a meeting held in Dublin in 2003 and supported by Johnson & Johnson, it is possible to conclude that long-acting risperidone has demonstrated efficacy and tolerability, even among patients who are considered clinically stable on other antipsychotics. Most patients can switch safely and effectively to long-acting risperidone if appropriate strategies are applied. Long-acting risperidone provides a new and promising therapeutic option for the treatment of schizophrenia.
Authors:
Samuel J Keith; Luca Pani; Beat Nick; Robin Emsley; Luis San; Martin Turner; Robert Conley; Paul Scully; Pierre S Chue; Bernard Lachaux
Related Documents :
14743199 - Chronic graft-versus-host disease: where do we go from here?
19628879 - Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analy...
17931389 - Outcome of primary root canal treatment: systematic review of the literature - part 1. ...
19407049 - Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systemati...
11840709 - A complication conference for internal quality control at the neurosurgical department ...
15494999 - Anaesthesia for hip fracture surgery in adults.
21707269 - Haemorrhagic shearing lesions associated with diffuse axonal injury: application of t2 ...
19175449 - Initial clinical experience with the new irrigated tip magnetic catheter for ablation o...
22658249 - Evaluation of peri-operative epidural analgesia with ropivacaine, ropivacaine and sufen...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Psychiatric services (Washington, D.C.)     Volume:  55     ISSN:  1075-2730     ISO Abbreviation:  Psychiatr Serv     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-03     Completed Date:  2005-01-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502838     Medline TA:  Psychiatr Serv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  997-1005     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, University of New Mexico, Albuquerque 87131-1161, USA. skeith@salud.unm.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / administration & dosage,  adverse effects,  therapeutic use*
Basal Ganglia Diseases / chemically induced
Delayed-Action Preparations / therapeutic use
Drug Tolerance
Health Promotion*
Humans
Patient Compliance*
Risperidone / administration & dosage,  adverse effects,  therapeutic use*
Schizophrenia / drug therapy*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Delayed-Action Preparations; 106266-06-2/Risperidone
Comments/Corrections
Comment In:
Psychiatr Serv. 2005 Jan;56(1):105; author reply 106-7   [PMID:  15637204 ]
Psychiatr Serv. 2004 Dec;55(12):1443; author reply 1443-4   [PMID:  15572577 ]
Psychiatr Serv. 2005 Jan;56(1):105-6; author reply 106-7   [PMID:  15637203 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Calcium-activated potassium channel triggers cardioprotection of ischemic preconditioning.
Next Document:  Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric ...